SCHEMBL1086079

SCHEMBL1086079

CCCCCCCCCCCCCCCCOCC(O)CCP(=O)(O)O

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LPAR5 Q9H1C0 4/20 0.65
USP2 O75604 1/20 0.57
HTT P42858 1/20 0.56
S1PR1 P21453 6/20 0.54
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C19 P33261 1/20 0.52
LPAR3 Q9UBY5 8/20 0.51
LPAR1 Q92633 5/20 0.51
S1PR2 O95136 5/20 0.50
S1PR3 Q99500 5/20 0.50
S1PR4 O95977 4/20 0.50
LPAR2 Q9HBW0 4/20 0.48
P2RY10 O00398 1/20 0.46
LPAR6 P43657 3/20 0.45
LPAR4 Q99677 3/20 0.45
PLA2G2D Q9UNK4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1086081 1.00 LPAR5 (0.65) LPAR5USP2HTTS1PR1CYP1A2
SCHEMBL1086055 0.84 LPAR5 (0.57) LPAR5USP2HTTS1PR1CYP1A2
SCHEMBL1086057 0.84 LPAR5 (0.57) LPAR5USP2HTTS1PR1CYP1A2
SCHEMBL1086073 0.84 LPAR5 (0.57) LPAR5USP2HTTS1PR1CYP1A2
SCHEMBL11005207 0.83 LPAR3 (0.66) LPAR5S1PR1LPAR3LPAR1S1PR2
SCHEMBL8933348 0.83 LPAR1 (0.59) LPAR5S1PR1LPAR3LPAR1S1PR2
SCHEMBL2059626 0.83 LPAR1 (0.59) LPAR5S1PR1LPAR3LPAR1S1PR2
SCHEMBL19257794 0.82 USP2 (0.74) LPAR5USP2HTTCYP1A2CYP3A4
SCHEMBL4523337 0.81 LPAR5 (0.66) LPAR5USP2HTTCYP1A2CYP3A4
SCHEMBL31145925 0.81 LPAR5 (0.60) LPAR5USP2HTTLPAR3LPAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153615-B2 Synthesis of glycerolipid carbamates and dicarbamates and their use as an antitumor compounds THE UNIVERSITY OF MANITOBA (CA) 2012-04-10 US disclosed
US-20090042811-A1 Synthesis of Glycerolipid Carbamates and Dicarbamates and Their Use as an Antitumor Compounds THE UNIVERSITY OF MANITOBA (CA) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042811-A1 Synthesis of Glycerolipid Carbamates and Dicarbamates and Their Use as an Antitumor Compounds PHOSPHO1, SGMS1, UGCG LPAR5 708/4885USP2 1122/4885HTT 4036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.